Pre-existing cardiovascular disease rather than cardiovascular risk factors drives mortality in COVID-19.
Age Factors
Aged
COVID-19
/ mortality
Cardiovascular Diseases
/ complications
Cohort Studies
Diabetes Mellitus
/ epidemiology
Female
Heart Disease Risk Factors
Hospital Mortality
Humans
Hypertension
/ epidemiology
Male
Mortality
Outcome and Process Assessment, Health Care
Risk Assessment
/ methods
SARS-CoV-2
/ isolation & purification
United Kingdom
/ epidemiology
Venous Thromboembolism
/ diagnosis
COVID-19
Cardiovascular disease
Cardiovascular risk factors
Diabetes
Hypertension
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
03 07 2021
03 07 2021
Historique:
received:
07
03
2021
accepted:
24
06
2021
entrez:
4
7
2021
pubmed:
5
7
2021
medline:
13
7
2021
Statut:
epublish
Résumé
The relative association between cardiovascular (CV) risk factors, such as diabetes and hypertension, established CV disease (CVD), and susceptibility to CV complications or mortality in COVID-19 remains unclear. We conducted a cohort study of consecutive adults hospitalised for severe COVID-19 between 1st March and 30th June 2020. Pre-existing CVD, CV risk factors and associations with mortality and CV complications were ascertained. Among 1721 patients (median age 71 years, 57% male), 349 (20.3%) had pre-existing CVD (CVD), 888 (51.6%) had CV risk factors without CVD (RF-CVD), 484 (28.1%) had neither. Patients with CVD were older with a higher burden of non-CV comorbidities. During follow-up, 438 (25.5%) patients died: 37% with CVD, 25.7% with RF-CVD and 16.5% with neither. CVD was independently associated with in-hospital mortality among patients < 70 years of age (adjusted HR 2.43 [95% CI 1.16-5.07]), but not in those ≥ 70 years (aHR 1.14 [95% CI 0.77-1.69]). RF-CVD were not independently associated with mortality in either age group (< 70 y aHR 1.21 [95% CI 0.72-2.01], ≥ 70 y aHR 1.07 [95% CI 0.76-1.52]). Most CV complications occurred in patients with CVD (66%) versus RF-CVD (17%) or neither (11%; p < 0.001). 213 [12.4%] patients developed venous thromboembolism (VTE). CVD was not an independent predictor of VTE. In patients hospitalised with COVID-19, pre-existing established CVD appears to be a more important contributor to mortality than CV risk factors in the absence of CVD. CVD-related hazard may be mediated, in part, by new CV complications. Optimal care and vigilance for destabilised CVD are essential in this patient group. Trial registration n/a.
Sections du résumé
BACKGROUND
The relative association between cardiovascular (CV) risk factors, such as diabetes and hypertension, established CV disease (CVD), and susceptibility to CV complications or mortality in COVID-19 remains unclear.
METHODS
We conducted a cohort study of consecutive adults hospitalised for severe COVID-19 between 1st March and 30th June 2020. Pre-existing CVD, CV risk factors and associations with mortality and CV complications were ascertained.
RESULTS
Among 1721 patients (median age 71 years, 57% male), 349 (20.3%) had pre-existing CVD (CVD), 888 (51.6%) had CV risk factors without CVD (RF-CVD), 484 (28.1%) had neither. Patients with CVD were older with a higher burden of non-CV comorbidities. During follow-up, 438 (25.5%) patients died: 37% with CVD, 25.7% with RF-CVD and 16.5% with neither. CVD was independently associated with in-hospital mortality among patients < 70 years of age (adjusted HR 2.43 [95% CI 1.16-5.07]), but not in those ≥ 70 years (aHR 1.14 [95% CI 0.77-1.69]). RF-CVD were not independently associated with mortality in either age group (< 70 y aHR 1.21 [95% CI 0.72-2.01], ≥ 70 y aHR 1.07 [95% CI 0.76-1.52]). Most CV complications occurred in patients with CVD (66%) versus RF-CVD (17%) or neither (11%; p < 0.001). 213 [12.4%] patients developed venous thromboembolism (VTE). CVD was not an independent predictor of VTE.
CONCLUSIONS
In patients hospitalised with COVID-19, pre-existing established CVD appears to be a more important contributor to mortality than CV risk factors in the absence of CVD. CVD-related hazard may be mediated, in part, by new CV complications. Optimal care and vigilance for destabilised CVD are essential in this patient group. Trial registration n/a.
Identifiants
pubmed: 34217220
doi: 10.1186/s12872-021-02137-9
pii: 10.1186/s12872-021-02137-9
pmc: PMC8254437
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
327Subventions
Organisme : Medical Research Council
ID : MR/R016372/1
Pays : United Kingdom
Organisme : NIHR BRC South London & Maudsley
ID : IS-BRC-1215-20018
Organisme : HDRUK
ID : HDRUK MR/S00310X/1.
Organisme : King's College London
ID : Prize Fellowship
Organisme : Medical Research Council
ID : MC_PC_17214
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_20058
Pays : United Kingdom
Organisme : NIHR BRC GSTT
ID : IS-BRC-1215-20006
Organisme : British Heart Foundation
ID : CH/1999001/11735 and RE/18/2/34213
Pays : United Kingdom
Organisme : Alzheimer's Society
ID : 171
Pays : United Kingdom
Références
Thorax. 2021 Apr;76(4):412-420
pubmed: 33408195
EClinicalMedicine. 2020 Nov;28:100574
pubmed: 33052324
PLoS One. 2019 Nov 25;14(11):e0225625
pubmed: 31765395
J Cardiovasc Electrophysiol. 2020 Dec;31(12):3077-3085
pubmed: 33017083
Circulation. 2018 Nov 13;138(20):e618-e651
pubmed: 30571511
Cancer Treat Res. 1995;75:95-112
pubmed: 7640169
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
Artif Intell Med. 2021 Jul;117:102083
pubmed: 34127232
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Arterioscler Thromb Vasc Biol. 2020 Aug;40(8):1818-1829
pubmed: 32510978
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Eur Heart J Cardiovasc Imaging. 2020 Jul 1;21(7):709-714
pubmed: 32391912
J Am Coll Cardiol. 2020 Aug 4;76(5):533-546
pubmed: 32517963
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
Heart. 2020 Dec 17;:
pubmed: 33334863
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
J Am Coll Cardiol. 2021 Jan 26;77(3):314-325
pubmed: 33478655
Eur Heart J. 2015 Nov 7;36(42):2921-2964
pubmed: 26320112
Eur Heart J. 2020 Jun 7;41(22):2130
pubmed: 32227076
Eur Heart J. 2020 Sep 1;41(32):3038-3044
pubmed: 32882706
Diabetes Care. 2018 Mar;41(3):513-521
pubmed: 29330152
Diabetes Care. 2018 Oct;41(10):2127-2135
pubmed: 30104296
Stat Med. 1999 Mar 30;18(6):681-94
pubmed: 10204197
BMC Med Inform Decis Mak. 2018 Jun 25;18(1):47
pubmed: 29941004
JAMA. 2020 Jun 23;323(24):2518-2520
pubmed: 32437497
Cardiovasc Pathol. 2021 Jan - Feb;50:107300
pubmed: 33132119
Eur Heart J. 2020 May 14;41(19):1821-1829
pubmed: 32383763
Lancet Diabetes Endocrinol. 2020 Oct;8(10):813-822
pubmed: 32798472
Eur J Heart Fail. 2020 Jun;22(6):967-974
pubmed: 32485082
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Eur Heart J. 2015 Nov 21;36(44):3075-3128
pubmed: 26320109
Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d
pubmed: 23824828
Rev Esp Cardiol (Engl Ed). 2020 Aug;73(8):669-672
pubmed: 32499016
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-833
pubmed: 32798471
BMJ. 2013 May 20;346:f2350
pubmed: 23692896